Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 2
- 主要终点
- Number of medical related problem (MRP)s identified by the pharmacist through retrospective chart reviews (Phase I)
研究概览
简要总结
This trial studies how well pharmacist-led transitions of care works in the outpatient oncology infusion center for patients with solid tumor. Having a pharmacist in the outpatient oncology infusion center may help to identify and correct medical related problems and improve overall patient and staff satisfaction. Patients receiving education may benefit from gaining a better understanding of their antineoplastic therapy. Understanding the side effects associated with the therapy may also help patients better be prepared to manage any adverse effects they may experience.
详细描述
PRIMARY OBJECTIVE:
I. To demonstrate the effectiveness of a clinical oncology pharmacist in the outpatient infusion center through education, and the identification and correction of medication related problem (MRP)s.
SECONDARY OBJECTIVE:
I. To evaluate overall patient and staff satisfaction with the added clinical oncology pharmacy education.
EXPLORATORY OBJECTIVE:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Solid tumor diagnosis
- •Starting day 1 of new antineoplastic infusion
- •English speaking (and/or English-speaking primary caregiver/proxy)
排除标准
- •Metastasis to the brain and/or central nervous system (CNS) with evidence of impaired cognition
- •Severe cognitive impairment including dementia with inability to consent to the study
结局指标
主要结局
Number of medical related problem (MRP)s identified by the pharmacist through retrospective chart reviews (Phase I)
时间窗: Up to 1 year
MRPs will be assigned to a specific category and the total number of MRPs in each category will be recorded. Categories include but are not limited to: incorrect dose, therapeutic duplication, drug not indicated, drug interaction, monitoring recommendation, drug allergy, or potential for adverse event.
Percent of MRPs corrected as a result of the clinical oncology pharmacist services (Phase II)
时间窗: Up to 1 year
In phase 2 (prospective) MRPs will also be recorded and categorized, but in addition the outcomes relating to each MRP pharmacist intervention will be recorded. MRPs found by the pharmacist will be communicated to the patient's oncologist or primary care provider, and the pharmacist will follow-up to see if changes were made.
次要结局
- Patient and provider satisfaction with the pharmacist-led education(Up to 1 year)